On December 17, 2025, Soligenix, Inc. (SNGX) announced positive results from Cohort 3 of its ongoing Phase 2a trial of SGX302 (synthetic hypericin) in patients with mild-to-moderate psoriasis. The patients in Cohort 3 were treated for 18 weeks, but in contrast to Cohorts 1 and 2 they were treated with an optimized gel formulation of synthetic hypericin. The three evaluable patients (one patient withdrew for personal reasons) showed improvements in the Investigator Global Assessment (IGA), the Psoriasis Activity and Severity Index (PASI), the simplified psoriasis index, the dermatology life quality index, and the Skindex-29 questionnaire. The results were similar or improved relative to those using the previous ointment formulation and the initial exploratory phase of the study has confirmed that SGX302 improves psoriatic lesions and is well tolerated.
